1.Clinical observations of hepatic encephalopathy.
Sung In HONG ; Ki Pyo HONG ; Sang Hwa LEE
Journal of the Korean Academy of Family Medicine 1991;12(8):58-64
No abstract available.
Hepatic Encephalopathy*
2.Some opinions of etiology, treatment and progress of hepatic coma in children, through 105 cases in the institute of pediatric
Journal of Practical Medicine 2002;435(11):44-47
A study was carried out on 105 pediatric patients with hepatic coma in the national institute of pediatric during 1991-1995 has shown that the main cause of hepatic coma in children was acute hepatitis - hepatic failure, the treatment was not complete. It should limit the use of sedatives and antipyretic agents for pediatric patients with hepatic coma. The disease's progress was poor. The rate of remission and disease free was 4.7%. This rate in the group of acute hepatitis - hepatic failure induce coma was 1.23%.
Hepatic Encephalopathy
;
Pediatrics
3.Hepatic Encephalopathy and Manganese Brain Neurotoxicity: MR Features.
The Korean Journal of Hepatology 2000;6(1):3-5
No abstract available.
Brain*
;
Hepatic Encephalopathy*
;
Manganese*
4.The role of L-ornithine-L-aspartate in the management of minimal hepatic encephalopathy among patients with liver cirrhosis: A systemic review and meta-analysis.
Henry Winston C. LI ; Maria Ana Louise M. NAIDAS ; Karen Anjela M. MONDRAGON ; Ruter M. MARALIT
Acta Medica Philippina 2018;52(1):94-103
OBJECTIVE: To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) in improving minimal hepatic encephalopathy in adult patients with liver cirrhosis.
METHODS: A search in PubMed, Cochrane Library, Google Scholar, and Medline was made obtaining four qualified randomized controlled trials. Studies included adult cirrhotic patients with minimal hepatic encephalopathy measured by the number connection test (NCT-A, B), figure connection test (FCT-A, B), picture completion, block design test, and critical flicker frequency (CFF) testing with a cut-off score of
RESULTS: Of the 29 studies identified, 4 fulfilled the inclusion criteria, which entailed analysis of 238 participants (LOLA: 116, Control: 122). Three out of the four studies were used in meta-analysis and one study was analyzed separately due to a difference in the neuropsychometric measure. The meta-analysis favored the experimental group (LOLA), with a mean difference of 2.29 (95% CI 0.72 - 3.86), p-value = 0.004, and an I2 of 18%.
CONCLUSION: LOLA provided great potential in managing encephalopathy since treating earlier related to better survival and prevention of disease progression. The results of our study supported such evidence and its use may be encouraged.
Human ; Fibrosis ; Hepatic Encephalopathy
5.Some hematological and biochemical changes in patients with hepatic coma due to the viral hepatitis
Journal of Practical Medicine 2002;435(11):38-42
A study on 105 patients diagnosed as hepatic coma due to the viral hepatitis in the Institute of Clinical Medicine and Tropical Diseases during 1989-1997 has shown that the rate of male patients was higher than this of female patients; most of cases were acute disease. The hepatic coma due to the viral hepatitis occurred mainly in ages of 15-45. The hepatic coma experienced the hyperuremia had apoor prognosis. The more low prothrombin, the more severer prognosis.
Hepatic Encephalopathy
;
Hepatitis, Viral, Human
6.Primarily study on the significance of serum gamma glutamyl transpeptidase ((-GT) in some hepatic diseases
Journal of Practical Medicine 2002;435(11):5-8
54 patients with acute viral hepatitis of which hepatic coma (8), uncompensate cirrhosis (17) and liver cancer (14) participated to a study have shown that the serum gamma glutamyl transpeptidase ((-GT) activity was slightly increased in patients with viral hepatitis coma and uncompensate cirrhosis. This was a bad sign the (-GT was highly increased in patients with liver cancer. The average serum (-GT activity was increased about 3 times in the acute viral hepatitis. But diagnostic value of (-GT was lower than this of SGPT
Liver Diseases
;
Serum
;
gamma-Glutamyltransferase
;
Hepatic Encephalopathy
8.Hyperammonemic hepatic encephalopathy management through L-ornithin-L-aspartate administration in dogs.
Jin Ok AHN ; Qiang LI ; Young Heun LEE ; Sei Myoung HAN ; Cheol Yong HWANG ; Hwa Young YOUN ; Jin Young CHUNG
Journal of Veterinary Science 2016;17(3):431-433
Seventeen dogs were treated with L-ornithin-L-aspartate (LOLA; experimental group). Three dogs were treated with lactulose recognized therapy (control group). Following LOLA administration, 15 dogs experienced a significant decrease in ammonia level (p < 0.05) and showed clinical signs of improvement. However, there were no clinical signs of improvement in two dogs, even though the ammonia level decreased. Conversely, the clinical signs of the control group also improved and the ammonia level decreased, although these changes were not significant (p > 0.05). These results suggest that LOLA is an effective drug to treat hyperammonemia in veterinary medicine.
Ammonia
;
Animals
;
Dogs*
;
Dipeptides*
;
Hepatic Encephalopathy*
;
Hyperammonemia
;
Lactulose
;
Veterinary Medicine